AAAAAA

   
Results: 1-10 |
Results: 10
WHO consensus conference on diet and cancer
Authors: Meyskens, FL Jungi, WF Gerber, M de Waard, F Heidemann, E Heim, ME Joossens, JV Salvini, S Trichopoulou, A Varela, G Wolfram, G
Citation: Fl. Meyskens et al., WHO consensus conference on diet and cancer, EUR J CAN P, 9(3), 2000, pp. 213-216
Ischemic colitis as the pritnary manifestation of an enbolizing lung cancer infiltrating the left pulmonary vein
Authors: Wohr, M Muck, R Ziegler, HR Heidemann, E
Citation: M. Wohr et al., Ischemic colitis as the pritnary manifestation of an enbolizing lung cancer infiltrating the left pulmonary vein, MED KLIN, 95(6), 2000, pp. 346-348
First-line chemotherapy for metastatic breast cancer in high-risk patients- Greater therapeutic effect with mitoxantron monotherapy than with combination therapy with 5-fluorouracil, epirubicin and cyclophosphamide
Authors: Heidemann, E Stoeger, H Souchon, R Hirschmann, WD Bodenstein, H Oberhoff, C Fischer, JT Schulze, M Clemens, M Andreesen, R Mahlke, M Konig, M Scharl, A Gruener, A Fehnle, K Kaufmann, M
Citation: E. Heidemann et al., First-line chemotherapy for metastatic breast cancer in high-risk patients- Greater therapeutic effect with mitoxantron monotherapy than with combination therapy with 5-fluorouracil, epirubicin and cyclophosphamide, ONKOLOGIE, 23(3), 2000, pp. 2-4
First-line monochemotherapy with mitoxantrone versus combination with fluorouracil, epirubicin and cyclophosphamide in high-risk metastatic breast cancer: A prospective randomized multicenter clinical trial
Authors: Heidemann, E Souchon, R Stoger, H Hirschmann, WD Bodenstein, H Oberhoff, C Fischer, JT Schulze, M Clemens, M Mahlke, M Konig, M Scharl, A Fehnle, K Kaufmann, M
Citation: E. Heidemann et al., First-line monochemotherapy with mitoxantrone versus combination with fluorouracil, epirubicin and cyclophosphamide in high-risk metastatic breast cancer: A prospective randomized multicenter clinical trial, ONKOLOGIE, 23(1), 2000, pp. 54-59
What do we know about the prevalence of pain caused by malignancy?
Authors: Heidemann, E
Citation: E. Heidemann, What do we know about the prevalence of pain caused by malignancy?, SCHMERZ, 13(4), 1999, pp. 249-252
Guidelines for cancer pain therapy
Authors: Adamietz, A Beck, D Gralow, I Grond, S Hanekop, G Hankemeier, U Heidemann, E Hoffmann, L Jage, J Kath, R Klaschik, E Kloke, M Kloke, O Lempa, M Lindena-Glaess, G Nauck, F Radbruch, L Sohn, W Strumpf, M Tietze-Schillings, G Tronnier, V Weber, M Zeilhofer, HU
Citation: A. Adamietz et al., Guidelines for cancer pain therapy, TUMORDIAGN, 20(4), 1999, pp. 105-129
Modern strategies in cancer pain treatment
Authors: Heidemann, E
Citation: E. Heidemann, Modern strategies in cancer pain treatment, ONKOLOGIE, 22(5), 1999, pp. 425-430
Pain therapy in internal medicine - Introduction
Authors: Diehl, V Heidemann, E
Citation: V. Diehl et E. Heidemann, Pain therapy in internal medicine - Introduction, INTERNIST, 40(2), 1999, pp. 131-132
Pain treatment in oncology
Authors: Heidemann, E
Citation: E. Heidemann, Pain treatment in oncology, INTERNIST, 40(2), 1999, pp. 168-175
Does adjuvant systemic therapy improve prognosis in breast cancer with 4-9axillary nodes and in the age group of 80 years or more?
Authors: Fritz, M Schmidt, B Heidemann, E Brinkmann, F Benohr, C Bittner, R von Gaisberg, U Herschlein, HJ Jipp, F Karg, C Kieninger, G Littmann, K Meisner, C Merkle, P Metzger, H Strosche, H Widmaier, G
Citation: M. Fritz et al., Does adjuvant systemic therapy improve prognosis in breast cancer with 4-9axillary nodes and in the age group of 80 years or more?, ONKOLOGIE, 21(5), 1998, pp. 394-400
Risultati: 1-10 |